论文部分内容阅读
本文研究了利福平不同剂型的生物利用度。用狗,家兔和健康人做了对比实验,发现利福平的脂肪性基质口服制剂的生物利用度较胶囊剂、片剂、栓剂都高,且对肝脏的毒性也较小。用非模型矩量分析法求出的AUC~(0→∞)和MRT可知:450mg的脂肪性基质口服制剂可以获得与600mg胶囊剂相似的血药水平。因而可以推测利福平的脂肪性基质口服制剂的剂量较胶囊剂可降低1/4—1/3。
This article studies the bioavailability of different formulations of rifampicin. Comparative experiments with dogs, rabbits and healthy people showed that the bioavailability of oral formulations of rifampicin was higher than that of capsules, tablets and suppositories, and less toxic to the liver. The results of AUC ~ (0 → ∞) and MRT calculated by non-model moment analysis show that 450mg fatty oral dosage form can obtain similar blood levels as 600mg capsules. Therefore, it can be inferred that the dosage of rifampicin for the oral administration of the fatty matrix can be reduced by 1 / 4-1 / 3 compared with the capsule.